LNAINasdaqPharmaceutical PreparationsFiscal year ends June 30
Lunai Bioworks Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026
$0.47−0.21 (-30.63%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.1280 (−95.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Lunai Bioworks Inc. reported revenue of $51.99K for the twelve months to Jun 30, 2026. Free cash flow was -$5.29M.
Revenue
$51.99K
TTM Q4 2026
Operating income
-$8.70M
TTM Q4 2026
Free cash flow
-$5.29M
TTM Q4 2026
EPS, diluted
-$1.06
FY2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $51.99K
- Net income
- -$3.56M
- EPS, diluted
- -$1.06
- Free cash flow
- -$5.29M
Thirteen years at a glance
Fiscal years 2011 to 2026, USD
Revenue
$51.99K
Gross profit
–
Operating income
-$8.70M
Net income
-$3.56M
EPS, diluted
-$1.06
Free cash flow
-$5.29M
Reported period